Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 8-K

LABORATORY CORP OF AMERICA HOLDINGS

Form 8-K May 18, 2015

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

May 18, 2015

(Date of earliest event reported)

LABORATORY CORPORATION OF

AMERICA HOLDINGS

(Exact Name of Registrant as Specified in its Charter)

Delaware 1-11353 13-3757370

(State or other jurisdiction of

Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

358 South Main Street,

Burlington, North Carolina 27215 336-229-1127

(Registrant's telephone number

(Address of principal executive offices) (Zip Code) (Registrant's telepholic including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[]	Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Iten	n 7.01 Regulation FD Disclosure

On May 18, 2015, Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced the launch of two new Hepatitis C Virus (HCV) drug resistance assays. The HCV NS5A and NS5B Drug Resistance Assays expand LabCorp's portfolio of HCV resistance tests that includes HCV GenoSur® NS3/4A, which was launched in 2011. These tests are available through Monogram Biosciences, a member of the LabCorp Specialty Testing Group, and a leader in the development and commercialization of innovative antiviral diagnostics.

99.1 Press Release dated May 18, 2015

Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABORATORY CORPORATION OF AMERICA HOLDINGS Registrant

By: /s/ F. SAMUEL EBERTS III

F. Samuel Eberts III

Chief Legal Officer and Secretary

May 18, 2015